A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin.
In this study we describe a human sulfated 30 kD protein (sp30) that is recognized by a monoclonal antibody raised against human vitronectin (mAb 8E6). Another monoclonal antibody raised against human vitronectin, mAb MaSp, and a polyclonal antiserum against vitronectin did not react detectably with sp30. Sp30, unlike vitronectin, is synthesized by a variety of non-hepatic human cell lines in culture, including cells of lymphoid origin. It is synthesized in sulfated form as indicated by metabolic labeling of MG-63 human osteosarcoma cells with 35SO4. Sp30 is an extracellular matrix protein as indicated by its association with the matrix of MG-63 cells after removal of the cells with EDTA and its fibrillar pattern by immunofluorescence of non-permeabilized confluent MG-63 cell monolayers detected with mAb 8E6. This antibody also stained short fibrils in human embryonic tissue. This pattern was distinct from the fainter diffuse staining obtained with mAb MaSp and the polyclonal antiserum to vitronectin, suggesting that the 8E6 staining in embryonic tissues was mostly due to sp30 rather than vitronectin. A polyclonal antiserum against bovine microfibril associated glycoprotein (MAGP) precipitated a [35SO4]-30 kD protein from [35SO4]-labeled MG-63 medium that co-migrated with a band precipitated by mAb 8E6. Double-labeling immunofluorescence studies of embryonic tissues showed an identical distribution of anti-bovine MAGP antiserum and mAb 8E6 staining. These data indicate that sp30 is the human homolog of bovine MAGP. Distinction between sp30 and vitronectin will be important in ascertaining the localization and function of both proteins. The findings that sp30 is sulfated and synthesized and secreted by a variety of cells in culture should aid in defining its role in microfibrillogenesis. That sp30 is secreted by cells of lymphoid origin suggests that it might also have a heretofore unsuspected role in immune responses.
Tomasini-Johansson
B R
BR
Cancer Research Center, La Jolla Cancer Research Foundation, CA 92037.
Ruoslahti
E
E
Pierschbacher
M D
MD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015152:Blotting, Northern; D002417:Cattle; D002460:Cell Line; D003285:Contractile Proteins / Q000032:analysis; D003429:Cross Reactions; D017077:Culture Media, Conditioned; D004622:Embryo, Mammalian / Q000737:chemistry; D000939:Epitopes / Q000276:immunology; D005109:Extracellular Matrix / Q000737:chemistry*; D016326:Extracellular Matrix Proteins / Q000276:immunology / Q000302:isolation & purification*; D005455:Fluorescent Antibody Technique; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D051379:Mice; D008970:Molecular Weight; D009363:Neoplasm Proteins / Q000276:immunology / Q000302:isolation & purification; D009928:Organ Specificity; D000072260:RNA Splicing Factors; D011817:Rabbits; D014407:Tumor Cells, Cultured; D019096:Vitronectin
D000911:Antibodies, Monoclonal; D003285:Contractile Proteins; D017077:Culture Media, Conditioned; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D009363:Neoplasm Proteins; D000072260:RNA Splicing Factors; D019096:Vitronectin; C016598:microfibrillar protein